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Abstract
Human bone marrow-derived mesenchymal stem cells (hBMSCs) are important for tissue
regeneration but their epigenetic regulation is not well understood. Here we investigate the
ability of a non-nucleoside DNA methylation inhibitor, RG108 to induce epigenetic changes
at both global and gene-specific levels in order to enhance mesenchymal cell markers, in
hBMSCs. hBMSCs were treated with complete culture medium, 50 μM RG108 and DMSO
for three days and subjected to viability and apoptosis assays, global and gene-specific
methylation/hydroxymethylation, transcript levels’ analysis of epigenetic machinery
enzymes and multipotency markers, protein activities of DNMTs and TETs, immunofluores-
cence staining and western blot analysis for NANOG and OCT4 and flow cytometry for
CD105. The RG108, when used at 50 μM, did not affect the viability, apoptosis and prolifera-
tion rates of hBMSCs or hydroxymethylation global levels while leading to 75% decrease in
DNMTs activity and 42% loss of global DNA methylation levels. In addition, DNMT1 was sig-
nificantly downregulated while TET1 was upregulated, potentially contributing to the sub-
stantial loss of methylation observed. Most importantly, the mesenchymal cell markers
CD105, NANOG and OCT4 were upregulated being NANOG and OCT4 epigenetically mod-
ulated by RG108, at their gene promoters. We propose that RG108 could be used for epige-
netic modulation, promoting epigenetic activation of NANOG and OCT4, without affecting
the viability of hBMSCs. DMSO can be considered a modulator of epigenetic machinery
enzymes, although with milder effect compared to RG108.
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Introduction
The promising results of clinical tests using human mesenchymal stem cells (hMSCs) make
them a relevant source for cellular therapy applications in a wide range of diseases and in
regenerative medicine. However, the epigenetic regulation underlying hMSCs is not well
understood. Pluripotency genes, such as POU5F1-POU-class-5-homeobox-1 (OCT4) and
NANOG-Homeobox (NANOG), are expressed in hMSCs [1,2] and constitute the core regula-
tory network that suppresses differentiation-associated genes, thereby maintaining the pluri-
potency of cells [3]. OCT4/NANOG genes were demonstrated to be involved in inhibiting
spontaneous differentiation in MSCs, via upregulating DNA methyltransferase 1 (DNMT1)
[4]. In addition, Ten eleven translocation 1 (TET1), an enzyme involved in active DNA
demethylation, is a NANOG protein partner and both proteins are associated with mainte-
nance of pluripotency and lineage commitment in embryonic stem cells [5]. TET1 is also
recruited by NANOG to enhance the expression of OCT4 [5]. Although recent investigations
have identified fundamental mechanisms involved in the maintenance of the undifferentiated
cell state, few studies have been focused on hMSCs.
Epigenetics refers to a change in a gene that is passed on through cell division but does not
involve DNA sequence change [6]. Chemical changes in the DNA molecule and histone pro-
teins may act by modifying the chromatin architecture and changing the accessibility of tran-
scription factors to gene regulatory elements. Therefore, these modifications are essential for
either maintaining cells in an undifferentiated state or directing them towards cell fate specifi-
cation. DNA methylation (5mC) and hydroxymethylation (5hmC) represent the most studied
epigenetic modifications within the DNA molecule itself. DNMT enzymes are implicated in
the DNA methylation mechanism and there is evidence that DNMT1 acts as a maintenance
methyltransferase, operating at replication forks [7]. DNMT3A and DNMT3B enzymes are
involved in the de novo acquisition of DNA methylation status, introducing cytosine methyla-
tion at previously unmethylated CpG sites [7,8]. On the other hand, the oxidation of methylcy-
tosine to hydroxymethylcytosine has been shown to underlie the active DNA demethylation
mechanism and TET enzymes are responsible for catalysing this reaction [9]. Generally,
unmethylated DNA is associated with permissive and open chromatin architecture, whereas
the presence of nucleosomes and condensed chromatin is related to methylated DNA at gene
promoters. However, the specific roles of epigenetic machinery enzymes in hMSCs require
investigation.
Since epigenetic control is closely related to gene regulation, epigenetic modulators have
been used to affect gene expression patterns and cell fate. RG108 [2-(1,3-dioxoisoindolin-
2-yl)-3-(1H-indol-3-yl) propanoic acid or N-Phthalyl-L-tryptofan] is a compound specifically
designed to block the active site of DNMTs [10]. The confirmed ability to reactivate several
tumour suppressor genes and the lack of cell toxicity [10,11] make RG108 a good candidate
for epigenetic modulation therapies. Several investigations have used RG108 for studying
mechanisms involved in human disorders as well as in physiological conditions [12–18]. How-
ever, only two studies have tested this compound in hMSCs. In 2015, Oh et al. reported that
RG108 could provide beneficial efficacy in treating ageing-related diseases by restoring the
altered methylation pattern [19]. In the follow up study, they showed that senescence pheno-
type brought by excessive DNMTs’ expression found in amyotrophic lateral sclerosis could be
controlled by RG108 [20]. The authors suggested that RG108 may provide a better efficacy of
hMSCs in stem cells therapy, since the cell function was restored with an improvement in their
stem cell potency, cell migration, oxidative stress protection and senescence.
Although RG108 was specifically designed to target DNMT enzymes, its effects on the epi-
genetic machinery itself as well as genome-wide effects are still not fully recognised. In
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addition, epigenetic regulation in hMSCs is also not completely understood. Therefore, in this
study we investigate the ability of RG108 to trigger global changes in DNA methylation and
hydroxymethylation in hMSCs, in addition to gene-specific effects on epigenetic machinery
and NANOG and OCT4. The study aims at better understanding the epigenetic regulation in
hMSCs and explores the possibility of using RG108 in hBMSCs-based cell therapies.
Materials and methods
Cell culture and differentiation
Cryopreserved human bone marrow-derived mesenchymal stem cells (hBMSCs) were pur-
chased from Lonza (Walkersville, MD, USA) at passage 2 (P2) and tested by Lonza for the
presence of viral nucleic acid from HIV, hepatitis B virus, and hepatitis C virus. Initially, cells
were seeded at 5,000–6,000 per cm2 and grown in complete culture medium composed of Dul-
becco’s modified Eagle high glucose medium (DMEM) with L-glutamine, supplemented with
10% fetal bovine serum (FBS), penicillin (100 U/ml) and streptomycin (100 mg/mL) (Gibco,
Carlsbad, CA, USA). Cells were maintained in a humidified incubator at 37˚C and 5% CO2
atmosphere.
Only cells at passages P5—P7 were used and cell synchronization was performed by serum
starvation for 24 h, after each initial plating for each experiment. The age of hBMSCs donors
was between 20 and 22 years.
To evaluate the cell phenotype, the expression of cell surface markers such as CD105/APC,
CD166/PE, CD34/FITC and CD45/PerCP (BD Biosciences, San Diego, CA, USA) were ana-
lysed by flow cytometry using a FACSCalibur flow cytometer connected to the CellQuest pro-
gram (BD Biosciences, USA).
In order to confirm multipotentiality, the cells were induced towards osteogenic and adipo-
genic differentiation as previously described [21]. For in vitro osteogenic differentiation, cells
were cultivated in osteogenic induction medium (Lonza, Walkersville, MD, USA) for 21 days.
In sequence, the Alizarin Red staining (AR) assay was performed. The quantification was mea-
sured in a spectrophotometric apparatus, at 562 nm, by comparing the samples to a standard
curve using a micro-plate reader (VersaMax, Molecular Devices, Sunnyvale, CA, USA). In
addition, gene expression analysis of RUNX2, an osteogenic marker, was performed. For in
vitro adipogenic differentiation, hBMSCs were cultured in adipogenic induction medium in
according to the manufacturer’s recommendation, using the induction and maintenance adi-
pogenic medium from LONZA (Walkersville, MD, USA), for 25 days. Afterwards, the cells
were fixed with 10% formalin and stained with oil red O (Merck Millipore, Darmstadt, Ale-
manha). In addition, gene expression analysis of adipogenic gene marker PPARgamma-2 was
performed.
RG108 preparation
RG108 was purchased from Sigma (St. Louis, MO, USA) and dissolved in DMSO (Sigma-
Aldrich, St. Louis, MO, USA) to make 200 mM stock solution [12] and stored at -20˚C until
further use. For control purposes, hBMSCs were also cultivated in standard medium with
DMSO (vehicle control).
Groups
After cell and drug characterization phase, experiments were carried out for 3 days and three
experimental groups were defined as follows:
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• DMEM: hBMSCs were cultivated in complete culture medium, supplemented with 10%
FBS, penicillin and streptomycin.
• DMSO: hBMSCs were cultivated in complete culture medium, supplemented with 10% FBS,
penicillin, streptomycin and 0.025% DMSO.
• RG108: hBMSCs were cultivated in complete culture medium, supplemented with 10% FBS,
penicillin, streptomycin and final concentration of 50 μM RG108.
Viability assay
Three biological replicates were used for each experiment. hBMSCs were seeded at 0,5 x 104
cells/well in a 96-well plate with standard medium and incubated for 24h. After the 24h incu-
bation and subsequent cell adhesion, cell starvation was performed for another 24h and then
the cell treatment was initiated. hBMSCs were cultivated for 7 days, with media change at day
3. Cells from the test group were cultivated with RG108 diluted in complete culture medium.
In the first set of experiments, high concentrations of RG108, such as 400 μM, 800 μM, 1.6
mM, were tested in two hBMSCs populations, for 7 days. In the second set, we tested lower
concentrations of RG108, such as 50 μM, 100 μM 200 μM, for 7 days in one hBMSCs popula-
tion. In the third set, we confirmed the results observed for 50 μM RG108 at 7 days (where cell
metabolic activity was the least affected) by performing three independent viability assays in
one hBMSCs population with a 3 days treatment. The cell viability was determined by the met-
abolic activity using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay (Sigma, St. Louis, MO, USA) according to the manufacturer’s instructions. Each of the
biological replicates was plated six times (technical replicates) for absorbance reading at 540
nm using VersaMax micro-plate reader (Molecular Devices, Sunnyvale, CA, USA).
Population doubling time assay
To determine the population doubling time (PDT), hBMSCs were seeded at 24 well plates at
three different densities with standard medium with or without 50 μM RG108. The experiment
was repeated three times. After adhesion, cells corresponding to the time 0 were fixed with 5%
trichloroacetic acid, lysed with NaOH (0.5 mol/L) and cell quantification was determined with
the spectrophotometric analysis at 260 nm. The remaining cells were fixed, lysed and quanti-
fied at 1, 2 and 3 days. The PDT was established by calculating the log natural l(n) for the initial
concentrations. Then, from a l(n) linear regression (l(n)–dependent variable x time–indepen-
dent variable) the angular linear coefficient was generated (μ). Calculations of PDT were done
from the following equation g = ln2/μ, where ln2 is 0.30103.
Apoptosis assay
Aiming to evaluate if RG108 at concentration of 50 μM and 100 μM could trigger cell death by
apoptosis, 3 x 105 cells were seeded in 100 mm dishes, cultivated in complete culture medium
and treated according to experimental groups for 3 days and 7 days. Cells were harvested and
freshly evaluated for apoptosis by flow cytometry using nucleic acid dye 7-Amino-Actinomy-
cin D (7-AAD) and phospholipid-binding protein Annexin V (BD Pharmingen, San Jose, CA
USA), as described by the manufacturer’s instruction. Cells were gated into four populations
and counted using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) con-
nected to the CellQuest software (BD Biosciences, USA). The non-apoptotic cells were sorted
into the lower left quadrant.
RG108 increases NANOG and OCT4 through epigenetic activation
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DNA, RNA and protein isolation
hBMSCs were seeded at 2.23 x 106 cells in 150 mm dishes in complete culture medium and
treated according to experimental groups. Two independent experiments were performed.
After 3 days cells were scraped off in PBS and divided into three eppendorf tubes for DNA,
RNA and protein extraction. DNA and protein tubes were stored at -80˚C until further use.
RNA tubes were quickly centrifuged in refrigerated centrifuge for pellet formation at 4˚C after
which 1 mL of TRIzol reagent (Gibco BRL, Life Technologies, Rockville, MD, USA) was added
to the pellet and samples were stored at -80˚C until further use.
Total RNA was isolated by TRIzol method, according to manufacturer’s recommendation,
DNase-treated (Turbo DNA-free, Ambion Inc., Austin, TX, USA) and 1 μg was used for com-
plementary DNA (cDNA) synthesis, using the First-Strand cDNA Synthesis Kit (Roche Diag-
nostic Co., Indianapolis, IN, USA). cDNA samples were stored at -20˚C.
Total DNA was purified by extraction with phenol/chloroform/isoamyl alcohol and DNA
samples were stored at -20˚C. DNA and RNA concentrations were determined using spectro-
photometer (Nanodrop 1000; Nanodrop Technologies LLC, Wilmington, NC, USA).
Total protein was extracted using EpiQuik Nuclear Extraction Kit I (Epigentek Group Inc.,
NY, USA) using 106 cells as input and 20 μL as a final volume. Subsequently, protein nuclear
extracts were quantified using Pierce BCA Assay (Thermo Scientific Inc., Brenner, Germany),
according to manufacturer’s recommendation and stored at -80˚C.
Global methylation assay
Global DNA methylation level analysis was performed using Imprint Methylated DNA Quan-
tification Kit (Sigma, St. Louis, MO, USA) as previously described [14] and according to man-
ufacturer’s instructions. Each DNA sample was used in five technical replicates. Methylated
control (50 ng/μL) was used for comparison of methylation levels (% of the methylated con-
trol) and the 450 nm absorbance was read in a VersaMax microplate reader (Molecular
Devices, Sunnyvale, CA, USA).
Global hydroxymethylation assay
For global hydroxymethylation levels, the Quest 5-hmC DNA Elisa kit (Zymo Research Corp.,
Irvine, CA, USA) was used and 100 ng DNA of each sample was plated five times for each
group, as previously described [22] and according to manufacturer’s recommendation. The
control DNA set containing a specified percentage of 5-hmC, supplied by the manufacturer,
was used to determine the hydroxymethylation quantification and the 450 nm absorbance was
read in VersaMax microplate reader (Molecular Devices, Sunnyvale, CA, USA).
DNMTs activity assay
5 μg of protein nuclear extract input for each sample was used to analyse DNMTs activity in
duplicate measurement with EpiQuik DNA Activity/Inhibition Assay Ultra Kit Colorimetric
(Epigentek Group Inc., NY, USA), as previously described [23] and according to manufactur-
er’s recommendation. The 450 nm absorbance was read in VersaMax microplate reader
(Molecular Devices, Sunnyvale, CA, USA).
Demethylases activity assay
5 μg of protein nuclear extract input for each sample was used to measure the demethylases
activity with Epigenase 5mC-Hydroxylase TET Activity/Inhibition Assay Kit (Epigentek
Group Inc., NY, USA) in duplicate as previously described [23] and according to
RG108 increases NANOG and OCT4 through epigenetic activation
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manufacturer’s recommendation. The 450 nm absorbance was read in VersaMax microplate
reader (Molecular Devices, Sunnyvale, CA, USA).
mRNA expression analysis
The DNMT1, DNMT3A, DNMT3B, TET1, TET2, SOX2, NANOG and OCT4 mRNA expres-
sion analysis was conducted in a real-time polymerase chain reaction (RT-PCR) apparatus
(LightCycler 480 Real Time PCR System; Roche Diagnostics GmbH, Mannheim, Germany)
with a SYBR Green Kit (FastStart Essential DNA Green Master; Roche Diagnostic Co., India-
napolis, IN, USA). Results were expressed as relative amounts of the target gene using β-actin
as inner reference gene. The details of the primers are presented in Table 1.
Quantitative PCR assay for gene-specific DNA methylation and
hydroxymethylation
Genomic DNA was initially treated with T4-β-glucosyltransferase (T4-BGT) (New England
Biolabs, Beverly, MA, USA), which adds glucose moiety to 5-hmC in order to distinguish
amongst DNA methylation and hydroxymethylation. For each sample, three tubes containing
400 ng gDNA each were processed (1X NE buffer 4, 40 mM UDP glucose, 1U T4-BGT) in a
final volume of 20 μL and incubated at 37˚C for 1 hour, followed by 10 min at 65˚C. Subse-
quently, samples were digested with methylation-independent MspI or methylation-sensitive
HpaII restriction enzymes (New England Biolabs, Beverly, MA, USA) or H2O (control), to a
Table 1. Primer sequences used for RT-qPCR.
Gene Primer 5’-3’ sequence Reactions Conditions
DNMT1 Forward GAGCCACAGATGCTGACAAA 95˚C–10”
60˚C– 10”
72˚C– 10”
Reverse GACACAGGTGACCGTGCTTA
DNMT3A Forward AAGGAGGAGCGGCCAGAG 95˚C– 10”
58˚C– 10”
72˚C– 23”
Reverse GGATGGGGACTTGGAGATCA
DNMT3B Forward GGGAGGTGTCCAGTCTGCTA 95˚C– 10”
60˚C– 10”
72˚C– 18”
Reverse GGCTTTCTGAACGAGTCCTG
TET1 Forwar TCATGGGTGTCCAATTGCTA 95˚C– 10”
61˚C– 09”
72˚C– 09”
Reverse GATGAGCACCACCATCACAG
TET2 Forward GGACATGATCCAGGAAGAGC 95˚C– 10”
55˚C– 10”
72˚C– 18”
Reverse CCCRCAACATGGTTGGTTCT
TET3 Forward CCCACAAGGACCAGCATAAC 95˚C– 10”
58˚C– 10”
72˚C– 23”
Reverse CCATCTTGTACAGGGGGAGA
NANOG Forward AGGGCTGTCCTGAATAAGCA 95˚C– 10”
56˚C– 10”
72˚C– 10”
Reverse GAGATGCCTCACACGGAGAC
OCT4 Forward CGCAAGCCCTCATTCAC 95˚C– 10”
60˚C– 06”
72˚C– 06”
Reverse CATCACCTCCACCACCTG
SOX2 Forward GCAAACTTCCTGCAAAGCTC 95˚C– 10”
57˚C– 10”
72˚C– 10”
Reverse GCAAACTTCCTGCAAAGCTC
ß-ACTIN Forward CCAACCGCGAGAAGATGA 95˚C– 10”
61˚C—10”
72˚C– 10”
Reverse CCAGAGGCGTACAGGGATAG
https://doi.org/10.1371/journal.pone.0207873.t001
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final volume of 25 μL at 37˚C for 1 hour. Tubes containing the HpaII restriction enzyme were
submitted to additional incubation for 10 min at 65˚C, for enzyme inactivation. Subsequently, 40
ng of gDNA was subjected to 40 amplification cycles using 0.5 μM of gene-specific primers and
gene-specific qPCR conditions (Table 2) in a final reaction volume of 10 μL. Amplicon locations
for DNMTs, TETs, OCT4 and NANOG were chosen at regulatory regions such as DNaseI hyper-
sensitivity clusters sites, layered by histone modifications marks, CpG-enriched regions and tran-
scription factors binding sites (https://genome.ucsc.edu). The primers were designed using
Primer3 [24] and further analysed for secondary structures and annealing temperatures by the
Beacon Designer, Free Edition (http://www.premierbiosoft.com/). Sequences and chromosome
location were confirmed by the in-silico PCR (https://genome.ucsc.edu/). qPCRs were performed
as described for mRNA expression. Each sample was run in three technical replicates. The com-
parative Ct method was used in analysis and samples were normalized by setting the control reac-
tion (only treated with T4-BGT, without enzymes digestion) as a calibrator.
Fluorescence microscopy
For microscopy analyses, the hBMSCs were cultured on glass coverslips and treated according to
experimental groups described earlier. After 3 days, cells were washed with PBS, fixed in PBS-para-
formaldehyde 4% for 1 h and permeabilized in PBS containing 0.2% Triton-X 100 and 1% BSA at
37˚C for 1 h and stained with primary antibodies diluted according to the manufacturer’s instruc-
tions: mouse monoclonal OCT4 (ab-59545, Abcam; 1:100 dilution) and mouse monoclonal
NANOG (1E6C4—sc-293121, Santa Cruz Biotechnology; 1:100 dilution) for 1 h at room tempera-
ture. After washing with PBS, the cells were stained with secondary antibody rabbit anti-mouse
Table 2. Primer sequences for gene specific DNA methylation and hydroxymethylation qPCR.
Gene Primer 5’-3’ sequence Reactions
Conditions
Product size
(bp)
Restriction enzymes sites position and
number of CCGG analysed
Number of CCGG excluded in
the analysed region
DNMT1 Forward TCGGGAGGCTTCAGCAGACG 95˚C– 15”
63˚C– 15”
72˚C– 15”
201 bp chr 19: 3 CCGG sites
10.194.943/10.195.008
10.195.079
0
Reverse TGCGTGTTCCCTGGGCAT
DNMT3A Forward GTCCCCGCATCCAGCAC 95˚C– 10”
57˚C– 10”
72˚C– 15”
200 bp chr 2: 3 CCGG sites
25.335.394/25.342.503
25.342.541
0
Reverse CTGAGGCAGGCAGAGCG
DNMT3B Forward TCAAATTTCCCTCGTCCCCG 95˚C– 10”
60˚C– 10”
72˚C– 10”
129 bp chr 20: 4 CCGG sites
32.762.284/32.762.322
32.762.343/32.762.348
8
Reverse GTGCCGACTCCCCTTGTAG
TET1 Forward GAGTTGGAAAGTTTGCCCGA 95˚C– 10”
57˚C– 10”
72˚C– 10”
211 bp chr 11: 4 CCGG sites
68.560.733/68.560.754
68.560.848/68.560.918
9
Reverse AGAGCCAAGGACGCAGAG
TET2 Forward CATCCCAACCTCCCACCTC 95˚C– 10”
56˚C– 10”
72˚C– 15”
479 bp chr 4: 10 CCGG sites
105.146.380/105.146.446
105.146.535/105.146.550
105.146.583/105.146.616
05.146.637/105.146.659
105.146.677/105.146.748
0
Reverse GGCGGACGTGACTTGCAT
TET3 Forward CTGTTTCCTAGCCGCATCAC 95˚C– 10”
57˚C– 10”
72˚C– 15”
198 bp chr 2: 1 CCGG site
74.002.302
18
Reverse CCACTCTCTAACCCCAGCAT
NANOG Forward CGAGACATAGACTATCTGCCTGA 95˚C– 8”
59˚C– 8”
72˚C– 8”
103 bp chr 12: 1 CCGG site
7.787.998
0
Reverse TTCTTCTCAGACTACCATTCCG
OCT4 Forward GAAATCCGAAGCCAGGTGTC 95˚C– 9”
63˚C– 9”
72˚C– 9”
195 bp chr 6: 1 CCGG site
31.170.643
0
Reverse TCCTTCGCCTCAGTTTCTCC
https://doi.org/10.1371/journal.pone.0207873.t002
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IgG H+L Alexa Fluor 488 (Invitrogen) for 1 h at room temperature. Cells were washed with PBS
and coverslips were mounted on glass slides using Fluoroshield with DAPI (Sigma) and then
viewed on Zeiss Axio Observer inverted microscope with Apotome.2 (Zeiss, Germany). The quan-
tification of NANOG and OCT4 was performed as previously described [25].
Western blotting analysis
The protein extracts were obtained and extracted in 500 μL Laemmli Buffer [SDS 4%, glycerol
20%, Tris-Cl (pH 6.8) 120 mM, bromophenol blue 0.02% (w/v) and DTT 0.1 M] and samples
were stored at -20˚C until further analyses. 15 mL protein (75 mg) was resolved by SDS-PAGE
and blotted onto Immobilon FL PVDF membranes (Millipore, Bedford, MA, USA), blocked
in Tris-buffered saline (TBS) with 0.05% Tween 20, albumin 2,5% (TBSTA) and incubated
overnight at 4˚C with NANOG (1E6C4—sc-293121, Santa Cruz Biotechnology) and OCT4
(ab-59545, Abcam) antibodies, followed by the appropriate horseradish peroxidase (HRP)-
linked secondary antibody, at 1:5000 dilution, in TBSTA for 1 h. The immunoreactive bands
were detected with enhanced chemiluminescence kit.
Flow cytometry of CD105
To evaluate the RG108 and DMSO effects in the MSCs surface molecule CD105, its expression
was analyzed by flow cytometry, after DMEM, RG108 and DMSO treatments for three days.
Cells were detached using a cell dissociation enzyme-free buffer (TrypLE, Gibco, Carlsbad,
CA, USA) to obtain single cell suspensions. Cells were suspended in blocking buffer for 40
minutes at 4˚C. Approximately 3 x 105 cells were incubated with mouse anti-human monoclo-
nal antibody against CD105-allophycocianin (eBioscience, USA) or isotype-matched control
for 40 min at 4˚C. Following washing, cells were analyzed using a FACSCalibur flow cytometer
(BD Biosciences, San Jose, CA, USA) connected to the CellQuest program (BD Biosciences,
USA). The results were expressed as percentage of positive cells on 10,000 events.
Statistical analysis
Data were initially examined for normality by Shapiro-Wilk test (or similar) and expressed as
mean ± standard deviation (SD). After normal data distribution was confirmed, One-way
analysis of variance (ANOVA α� 0.05) followed by pairwise multiple-comparison test
(Tukey) were used to identify the difference amongst groups; otherwise, the Kruskal-Wallis,
followed by the Dunn’s Multiple Comparison Test were employed (GraphPad Prism 7 –
GraphPad Software Inc., San Diego, CA, USA).
Results
hBMSCs phenotyping and differentiation
To confirm undifferentiated state of hBMSCs, flow cytometry analysis was performed, and the
cells presented expression of CD105 and CD166 (98.94%). Additionally, hBMSCs showed lack
expression of CD45 and CD34 (98.27%) (Fig 1). The osteogenic (Fig 1C–1H) and adipogenic
(Fig 1I–1K) potential also was evaluated. The osteogenic induced-hBMSCs were able to differ-
entiate into osteoblasts confirmed by the presence of mineral deposits after Alizarin red stain-
ing (p� 0.0001) (Fig 1E–1G) at 21 days of osteogenic induction; in addition, the cells showed
increase in the RUNX2 transcript levels (Fig 1H), when compared to the control group (not
induced) (p� 0.001). The hBMSCs were able to differentiate into adipocyte, after 25 days of
adipogenic induction (Fig 1J), presenting lipid vacuoles stained by oil Red O and increase in
the transcript levels of PPARgamma-2 (p� 0.0001).
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Effect of RG108 on viability and apoptosis in human bone marrow-derived
mesenchymal stem cells (hBMSCs)
The optimal RG108 treatment in hBMSCs would result in DNA demethylation and enhance
the cells’ multipotency without any toxic effects. Therefore, we first tested different inhibitor
concentrations for their effects on cell viability, apoptosis and population doubling times. In
the first set of experiments, two hBMSCs populations were treated for 7 days with high con-
centrations (400 μM, 800 μM and 1.6 mM) of the compound. Significant decrease in cell viabil-
ity was observed in all of them when compared to DMEM and 1.6 mM compared to DMEM
and DMSO controls (Fig 2A and 2B). Subsequently 50 μM, 100 μM, 200 μM RG108 treatments
were tested at day 7 in one of the hBMSCs populations (Fig 2C). Metabolic activity was not
affected when the cells were treated with 50 μM of the compound. After choosing 50 μM as
optimal concentration, the hBMSCs’ viability was again evaluated at day 3. The observed
decrease in cell’s viability is about 5% in the RG108 and DMSO-treated groups comparing to
DMEM therefore the effect was small even if significant (Fig 2D).
In addition, an apoptosis assay was performed at Day 3 and 7, for 50 μM and 100 μM of
RG108. Again, no differences were observed, with DMEM group having 98.69% of intact cells
and DMSO and RG108 (50 μM and 100 μM) groups having 98.06%, 99.22% and 97.49%,
respectively (Fig 3A) at 3 days; similar results were obtained at 7 days (Fig 3B).
The population doubling time (PDT) of RG108/50 μM-treated cells did not differ from the
control cells (43.73h and 43.23h, respectively), demonstrating that 3 days of 50 μM RG108
treatment does not affect the ability of hBMSCs to proliferate in vitro (Fig 3C).
Effect of RG108 on global DNA methylation and hydroxymethylation levels
The global DNA methylation was assessed by a colorimetric assay. After samples were com-
pared to the methylated control sample, the methylation levels were observed to be
Fig 1. hBMSCs phenotyping and differentiation. Dot plot graphs illustrate the presence/absence of mesenchymal cell
surface markers, performed by flow cytometry analysis on hBMSCs. (A) CD166 and CD105 positive cells are sorted
into the upper right quadrant (UR) (98.94%) and (B) CD34 and CD45 negative cells are sorted into the lower left (LL)
(98.27%). The results were obtained by flow cytometry performed in FACS Calibur flow cytometer (BD Biosciences,
San Jose, CA, USA). (C) Representative photomicrograph of osteogenic differentiation with 10x magnification of
control group (standard medium—DMEM 10%) and (D) osteogenic group (osteogenic induction medium). (E)
Alizarin red staining after 21 days of osteogenic induction with standard culture medium—DMEM 10% and (F)
osteogenic medium and (G) levels of alizarin red concentration in both groups; (H) RT-PCR analysis of RUNX2 gene
expression. Representative photomicrograph of adipogenic differentiation (10x magnification) after 25 days of
induction, (I) control group cultured in standard medium–(DMEM 10%) and (J) adipogenic induction medium; (K)
RT-PCR analysis of gene expression of PPARgamma-2. For all graphics, � above the bars represent significant inter-
group differences when compared to DMEM. �� and ��� indicate, respectively, p� 0.001 p� 0.0001 by the test T
student.
https://doi.org/10.1371/journal.pone.0207873.g001
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significantly lower in cells treated with 50 μM of RG108 for 3 days when compared to DMEM
and DMEM/DMSO (p� 0.001) groups. Addition of DMSO alone did not affect the methyla-
tion levels (Fig 4A). Next, a colorimetric assay was used to analyse global DNA hydroxymethy-
lation levels. After samples were compared to the hydroxymethylated control sample, both
RG108 and DMSO treated cells showed lower levels of global hydroxymethylation comparing
to the DMEM group, however, these differences were not statistically significant (Fig 4B).
Fig 2. Effect of RG108 on hBMSCs cell viability. (A, B) 2 populations of hBMSCs were treated with 400 μM, 800 μM
and 1.6 mM of RG108 for 7 days, showing significant reduction in viability comparing to DMEM and DMSO control
groups. (C) Population 1 was treated with 200 μM, 100 μM and 50 μM of RG108 for 7 days; only 50 μM showed similar
metabolic activity to DMEM group. (D) Population 1 was treated with 50 μM RG108 for 3 days confirming this
concentration has little effect on hBMSCs viability. Three biological replicates were used for each experiment and each
one was plated in six technical repeats and the cells’ metabolic activity was measured using the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The data are presented relative to DMEM group as mean and
standard deviation. For all graphics, asterisks above the bars represent significant inter-group differences when
compared to DMEM. Other significant differences are represented by asterisks above the linkers. �, �� and ��� indicate,
respectively, p� 0.01, p� 0.001 p� 0.0001 by ANOVA One Way followed by the Tukey test (c and d) and by
Kruskal-Wallis followed by the Dunn’s Multiple Comparison Test (a and b).
https://doi.org/10.1371/journal.pone.0207873.g002
Fig 3. Effect of RG108 on apoptosis in hBMSCs. (A, B) hBMSCs were treated for 3 and 7 days with 50 μM and
100 μM RG108 and compared to DMEM and DMSO controls. Neither of the treatments triggered cell death by
apoptosis at 3 and 7 days. The non-apoptotic cells are sorted into the lower left (LL) quadrant. (C) Three days of 50 μM
RG108 treatment did not affect also the hBMSCs’ ability to proliferate in vitro. Two biological replicates were
performed for each group; data are presented as l(n) of cells seeded at three different densities and quantified
spectrophotometrically at 260 nm.
https://doi.org/10.1371/journal.pone.0207873.g003
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RG108 reduces the DNMTs’ activity while DMSO is responsible for an
increase in the TETs’ activity
Since the RG108 compound was specifically designed to block the DNMTs active site and a decrease
in the global methylation levels was observed, it was expected to see a decrease in the DNMTs’ activ-
ity in nuclear protein extracts. Indeed, there was a significant (63%) reduction in the DNMTs activ-
ity levels for 50 μM RG108 when compared to both DMEM (p� 0.0001) and DMSO-treated cells
(p� 0.05). A small although significant decrease in DNMTs’ activity was also observed for DMSO-
treated cells (Fig 4C); however, this was not sufficient to affect global DNA methylation levels (Fig
4A). The activity levels of demethylases (TETs) were also evaluated and a significant increase was
observed, to a similar extent, comparing to DMEM, for both DMSO and RG108 treated cells (Fig
4D). However, the effect was bigger for DMSO, comparing to RG108 (p� 0.01).
RG108 changes gene expression of epigenetic machinery enzymes and
multipotency markers
Although the decrease in DNMTs’ activity after RG108 treatment can be explained by blocking
the DNMT1 active site by the compound, we further investigated whether DNMT1, DNMT3A
Fig 4. Global effects of RG108 on DNA modifications and DNMTs and TETs enzymatic activities in hBMSCs. hBMSCs were treated with 50 μM
RG108 for 3 days and compared to DMEM and DMSO controls. (A) Global methylation was assessed using Imprint Methylated DNA Quantification Kit
showing a significant decrease in the RG108 group. (B) Global hydroxymethylation was analyzed using Quest 5-hmC DNA Elisa kit; no statistical
differences are observed amongst groups. DNMTs (C) and TETs (D) enzymatic activities were assessed using colorimetric assays. Global methylation and
hydroxymethylation experiments were performed in biological triplicates and DNMTs and TETs activities were performed in biological duplicates. For all
graphics, �� or ��� above the bars represent significant inter-group differences when compared to DMEM. Other significant differences are represented by
� symbol above the linkers. �� and ��� indicate, respectively, p� 0.001 and p� 0.0001 by ANOVA One Way followed by the Tukey test.
https://doi.org/10.1371/journal.pone.0207873.g004
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and DNMT3B genes transcripts were also affected. Results demonstrated a large, 50%-95%,
decrease in DNMTs transcript levels in RG108 (DNMT1) and DMSO-treated cells (DNMT3A
and DNMT3B) compared to DMEM control which could contribute to the substantial loss of
methylation observed in hBMSCs. For the maintenance DNMT1, the most highly expressed
DNA methyltransferase in these cells, the decrease was also significant when compared to the
DMSO control samples (p� 0.001) (Fig 5A–5C).
In addition to the effect on DNMT1, RG108 treatment appears to upregulate the expression
of TETs, mostly TET1. A significant increase in TET1 mRNA level was observed in RG108-
treated cells when compared to both DMSO (p� 0.05) and DMEM (p� 0.001) groups (Fig
5D). Although DMSO did not modulate TET1 transcripts, the DMSO-promoted increase in
the TET2 gene expression was statistically significant, comparing to DMEM (p� 0.001) (Fig
5E). We did not detect any PCR product for TET3 and it is possible this enzyme is not
expressed or very low expressed in hBMSCs.
Fig 5. Changes in transcript levels of epigenetic machinery genes and multipotency markers after RG108 treatment. DNMT1 (A), DNMT3A (B), DNMT3B
(C), TET1 (D), TET2 (E), NANOG (F), OCT4 (G) and SOX2 (H) mRNA levels were analyzed by qPCR after 3 days of treatment with 50 μM of RG108. Results
correspond to mRNA levels ratio normalized to the β-actin levels. Determination of gene expression relative levels was performed using the cycle threshold (Ct)
method and the results are presented as mean/SD. Two biological replicates were performed for each group and each of the biological replicates was analyzed in
technical triplicates. For all graphics, �, �� or ��� above bars represent significant inter-group differences when compared to DMEM. Other significant differences
are represented by � symbol above the linkers. �, �� and ��� indicate, respectively, p� 0.01, p� 0.001 p� 0.0001 by ANOVA One Way followed by the Tukey test.
https://doi.org/10.1371/journal.pone.0207873.g005
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mRNA levels of SOX2 (RG108 X DMSO p� 0.0001; RG108 X DMEM p� 0.0001),
NANOG (RG108 X DMSO p� 0.001; RG108 X DMEM p� 0.001) and OCT4 (RG108 X
DMSO p� 0.0001; RG108 X DMEM p� 0.001) were significantly increased in RG108-treated
cells and this effect was independent of DMSO (Fig 5F–5H).
Gene-specific changes in methylation and hydroxymethylation after RG108
treatment
Methylation and hydroxymethylation changes at DNMT1, DNMT3A, DNMT3B, TET1, TET2,
TET3, NANOG and OCT4 genes were evaluated by quantitative-methylation-PCR assay
method. The analysed regions are within the promoters (+/-1.5kB from the transcription start
site) and are characterized by H3K4Me1, H3K4Me3 and H3K27Ac marks, DNA I hypersensi-
tivity clusters and regulatory elements as well as increased density of CpG sites.
All analysed regulatory regions for DNMTs were in mostly unmethylated state (20–30%
methylation) therefore permissive of transcription (Fig 6A). Any RG108 or/and DMSO-trig-
gered increases in methylation were very small (2–3%) and unlikely to account for the substan-
tial changes in gene expression (Fig 5). Similarly, there was no change in hydroxymethylation
levels at these genes.
On the other hand, both TET1 and TET2 (but not TET3) genes have demonstrated a statis-
tically significant decrease in the methylation levels for the RG108 group, comparing to
DMEM (p� 0.01) (Fig 6C) which corresponds with the increase in their transcript levels (Fig
5). An additional modulation in the hydroxymethylation levels in the TET1 gene (p� 0.01)
was observed in the RG108 group, comparing to DMEM and DMSO groups (Fig 6D).
Bigger changes after RG108 treatment were observed at the multipotency genes. The
NANOG gene demonstrated a statistically significant 40% loss of methylation comparing to
DMSO (p� 0.01) and to DMEM (p� 0.01) (Fig 6E). The hydroxymethylation levels were also
significantly lower for the RG108 group (Fig 6F) (p� 0.01 comparing to DMEM and DMSO).
Furthermore, the methylation and hydroxymethylation levels at the OCT4 gene region were
significantly reduced (almost 50% loss of methylation) for the RG108 group, when compared
to the DMEM group (p� 0.01) (Fig 6E) and the hydroxymethylation loss was also significantly
different between the RG108 and DMEM group (p� 0.01) (Fig 6F).
RG108 increases the mesenchymal stem cell markers NANOG, OCT4 and
CD105
In line with the gene expression results, an increase in the OCT4 and NANOG immunostain-
ing was observed in the RG108-treated cells (Fig 7A, 7B and 7C), as well as in the OCT4 and
NANOG protein content, with statistical difference for OCT4 (RG108 X DMSO p� 0.001;
RG108 X DMEM p� 0.001) (Fig 7D, 7E and 7F). These data corresponded to the increased
gene expression observed for NANOG and OCT4 (Fig 5F and 5G).
The mesenchymal cell surface marker CD105 was increased after DMSO treatment (~1.5
times) (Fig 8C); however, the RG108 treatment promoted bigger changes, increasing the
CD105 positive signal from 77.05 (DMEM group, Fig 8B) to 198.97 (RG108 group—~2.5
times more, Fig 8D).
Discussion
Improvement of cell therapy efficacy is one of the main goals in regenerative medicine and
hMSCs have been extensively studied for this purpose. However, their epigenetic regulation
remains to be elucidated. Epigenetic mechanisms contribute significantly to phenotype
RG108 increases NANOG and OCT4 through epigenetic activation
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Fig 6. Changes in DNA modifications at gene-specific regulatory elements in response to RG108 treatment. Methylation and hydroxymethylation levels were
analyzed by DNA glycosylation followed by restriction enzyme analysis and qPCR of promoter sequences, after 3 days of 50 μM RG108 treatment and compared to
DMEM and DMSO controls. The relative levels were determined using the cycle threshold (Ct) method and the methylation results are presented as HpaII levels—MspI
levels/control levels and the hydroxymethylation results are presented as MspI levels/control levels (% of control). Two biological replicates were performed for each
group and each of the biological replicates was done in technical triplicates. (A) All DNMT genes are mostly unmethylated (20–30% methylation level) and undergo only
small (2–3%) methylation after RG108. (B) The hydroxymethylation levels at DNMTs’ promoters are low and do not change after RG108 treatment. (C) TET genes have
similar 20–30% methylation levels; TET1 and TET2 undergo small but significant demethylation after RG108. (D) Hydroxymethylation levels at TET genes are low and
do not change with RG108. (E) RG108 treatment resulted in 40% and 40% loss of methylation and hydroxymethylation, respectively at NANOG regulatory element. (F)
For OCT4, the methylation loss was 48% and hydroxymethylation was 32%. For all graphics, �, �� or ��� above the bars represent significant inter-group differences
when compared to DMEM. Other significant differences are represented by � symbol above the linkers. �, �� and ��� indicate, respectively, p� 0.01, p� 0.001
p� 0.0001 by ANOVA One Way followed by the Tukey test.
https://doi.org/10.1371/journal.pone.0207873.g006
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changes and cell fate specification. Therefore, understanding the hMSCs epigenetics is crucial
for planning and executing stem cell-based therapies. This study aimed to test whether the
DNMT1 inhibitor, RG108, can be used to increase mesenchymal cell markers in hBMSCs and
to investigate the underlying epigenetic mechanisms. The results show that treatment of
hBMSCs with 50 uM RG108: (i) has no cytotoxic effects; (ii) leads to significant loss of global
DNA methylation; (iii) results in significant increase in RNA and protein levels of NANOG
and OCT4 that correlates with a local decrease in DNA methylation at their regulatory ele-
ments; and (iiii) increases the mesenchymal cell surface marker CD105.
RG108 is a non-nucleoside inhibitor that blocks the DNMT1 active site and shows fewer
side effects than other inhibitors [10]. Importantly, recent investigations have suggested that
RG108 may provide increased hMSCs efficacy in stem cell therapy [19,20]. In the present
study RG108, when used at 50 μM and 100 μM, showed lack of toxicity and did not trigger cell
death by apoptosis or changes in the cells’ ability to proliferate in vitro. These results are in line
with previous observations reported for hBMSCs [19,20]. Such observations might be cell
type-specific and dependent on epigenetic background as in human prostate cancer cells simi-
lar concentrations of RG108 led to growth inhibition and apoptosis [14].
hBMSCs have never been subjected to global epigenomic analysis after RG108 treatment.
As expected, our results showed a substantial (75%) decrease in the DNMTs activity and this
was followed by a reduction in global DNA methylation levels. The observed decrease was
Fig 7. RG108-trigerred changes to multipotency gene markers. hBMSCs were treated with 50 μM of RG108 for 3 days and subject to immunostaining (A, B and C)
and western blot (D, E and F) analysis. Untreated (DMEM) and vehicle control-treated (DMSO) cells were used as controls. Two biological replicates were performed
for each group. The data show a significant increase in the immunostaining of NANOG (A and B) and OCT4 (A, C, D and F). Representative images are shown in A
and D. Nuclei were labelled with DAPI (blue). Magnification x40. For all graphics, �� over the bars represent significant inter-group differences when compared to
DMEM. Other significant differences are represented by � symbol above the linkers. �� and ��� indicate, respectively, p� 0.001 p� 0.0001 by ANOVA One Way
followed by the Tukey test.
https://doi.org/10.1371/journal.pone.0207873.g007
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approximately 42% in RG108 group and this result is much higher than 10% reported by
Grac¸a et al. in prostate cancer cell lines [14]. Although RG108 works primarily through block-
ing DNMT1 catalytic site we also observe a large decrease in DNMT1 transcripts which could
contribute to the extensive demethylation observed. Interestingly, this downregulation was
also reported in prostate cancer cells after RG108 treatment [14]. The mechanism of DNMTs
suppression is not known and the observed small increase (~2%) in promoter methylation is
unlikely to be responsible for it. DNMTs contribute to formation of higher-order chromatin
structure leading to gene silencing [26–28]. The iPS reprogramming process requires an open
chromatin state [29] and DNMTs might suppress a decondensation process of the chromatin
and therefore prevent the accessibility of the reprogramming factors to their target regions.
RG108 has been previously used in iPS reprogramming and it is possible its effects on DNMTs
and chromatin structure are similar to these observed in hBMSCs.
It is also probable that RG108 could affect, through secondary mechanisms, the DNA
hydroxymethylation levels and demethylases activity, but this has never been studied. Here we
show that TET1 expression was upregulated which suggests that the hydroxymethylation levels
could increase if longer treatment was applied. This could additionally contribute to the
decrease in DNA methylation. The upregulation of TET1 and TET2 genes correlated with a
significant decrease in local methylation and, for TET1, increase in hydroxymethylation levels.
Most importantly, RG108 treatment in hBMSCs leads to a significant upregulation of two
multipotency genes, NANOG and OCT4, which was observed at mRNA level by gene expres-
sion analysis and protein, by immunostaining and western blot analysis. The upregulation of
NANOG and OCT4 correlates with RG108-trigerred decrease in methylation and hydroxy-
methylation at their regulatory elements. Some studies have shown that TET1 transcript levels
are regulated by OCT4, a multipotency marker and it can play an important role in DNA
hydroxymethylation and methylation during cells reprogramming [30]. To be considered mes-
enchymal stem cells, cells must express specific surface markers, such as CD105 [31]. Also
known as Endoglin, CD105 is a transmembrane receptor for TGF-ß family and it is expressed
in hBMSCs [32]; its activation is associated with cell proliferation and osteogenic
Fig 8. Effect of RG108 on CD105 surface marker. Flow cytometry histograms of hBMSCs showed modulation of CD105 surface marker, after RG108 and DMSO
treatments, for three days. hBMSCs were labelled with allophycocyanin (APC)-conjugated monoclonal antibody; positive cells are located at M2 region and M1
represents isotype as control.
https://doi.org/10.1371/journal.pone.0207873.g008
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differentiation [33] through TGF-ß signaling pathway (smad-dependent/smad-independent
and/or MAPK signaling). In addition to the upregulation of NANOG and OCT4,
RG108-treated cells showed upregulation of CD105 (~2.5 times), a well-known MSCs surface
marker. This increase was also observed in mesenchymal cells derived from human periodon-
tal ligament (hPDLSCs) (data not shown), although we did not observe the increase in the
NANOG and OCT4 at mRNA and protein levels in hPDLSCs (data not shown); therefore, the
RG108 effect might be cell specific. In addition, the compound was not tested during cell dif-
ferentiation processes, such as adipogenic or osteogenic induction.
Previously, TET1 and NANOG proteins have been shown to co-occupy genomic loci of
genes associated with the maintenance of pluripotency and lineage commitment [5]. Further-
more, NANOG recruit TET1 to enhance the expression of multipotency markers such as
OCT4 [5]. Subsequently Olariu et al., proposed a model in which the regulatory network of
OCT4, NANOG and TET1 includes positive feedback loops involving DNA-demethylation
around OCT4 and TET1 promoters [34]. Although the present investigation was performed in
hBMSCs, OCT4, NANOG and TET1 play similar roles to those in embryonic stem cells and
are essential for epigenetic regulation of cell multipotentiality. Epigenetics changes such as
DNA hydroxymethylation promoted by TET1 are important to modulate regulatory regions
of multipotency markers [30] and TET1 is capable of modulating DNA methylation levels at
CpG-rich promoters of multipotency markers, as OCT4 [30]. Our results show that RG108
treatment could in fact affect this complex.
Based on the obtained results and published data we propose a mechanism of RG108 action
in hBMSCs which originates from an inhibition of the enzymatic activity of DNMTs, leading
to a global decrease in DNA methylation and a local decrease of methylation levels at the pro-
moters of OCT4 and NANOG which, in turn, would upregulate their RNA and protein con-
tent. In addition, downregulation in DNMT1 expression and an increase in TET1 expression
and activity would further enhance global loss of methylation. The global loss of methylation,
high levels of OCT4/NANOG/TET1 and changes in their epigenetic patterns could then pro-
mote a more permissive chromatin therefore reinforcing the state of multipotency in hBMSCs,
since OCT4/NANOG/TET1 are well known to promote cell multipotency.
Due to rigorous use of vehicle (DMSO) control we could observe the DMSO effects on epi-
genetic regulation and dissociate them from the effects of RG108. DMSO was responsible for
the change in TETs activity and contributed to the modulation of DNMT3A, DNMT3B and
TET2 gene expression. DMSO has been previously reported to affect epigenetic regulation,
possibly through interactions with DNA and substrates like AdoMet [35,36]. Therefore, taking
previously published reports and results obtained in this study the DMSO might act as a mod-
ulator of the epigenetic machinery genes and this possibility should be taken into account
when using DMSO as a vehicle. However, it should be underlined that in the present study
only RG108 but not DMSO had a significant impact on multipotency genes expression and
their DNA methylation/hydroxymethylation levels. Therefore, the suggested supportive role of
RG108 in hBMSCs-based stem cell therapies is due to the drug itself.
Conclusions
When used at 50 μM, RG108 is a non-cytotoxic demethylating agent, triggering changes in
DNA methylation/hydroxymethylation levels, enzymatic activity of epigenetic machinery and
increases mesenchymal cell markers such as NANOG, OCT4 and CD105, in hBMSCs. The
epigenetic modulation might be involved in the chromatin remodelling, leading to a more per-
missive chromatin state and these changes could contribute to the proposed role of RG108 in
improving the efficacy of stem cell therapies. DMSO also triggered changes, suggesting that
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DMSO can be considered a modulator of epigenetic machinery enzymes, although with milder
effect compared to RG108.
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